Pharmaceutical Technology on MSN
Regeneron signs $2.32BN deal with Parabilis for Helicon conjugates
Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions.
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from ...
Zacks Investment Research on MSN
Regeneron & Parabilis sign oncology collaboration worth up to $2.2B
Regeneron Pharmaceuticals REGN has entered into a strategic research collaboration with clinical-stage biopharmaceutical ...
Regeneron Pharmaceuticals will partner with Parabilis Medicines to discover and develop an initial five candidates ...
Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class ...
Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3 billion, Parabilis Medicines has decided to ...
Parabilis Medicines today announced a strategic research collaboration with Regeneron Pharmaceuticals, Inc. to discover and ...
Agreement provides for Parabilis to receive $125M from Regeneron, including a $50M upfront payment and a $75M equity commitment, with up to approximately $2.2B in additional potential milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results